Cargando…

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

BACKGROUND: Risk-assessment of endometrial cancer (EC) is based on clinicopathological factors and molecular subgroup. It is unclear whether adding hormone receptor expression, L1CAM expression or CTNNB1 status yields prognostic refinement. METHODS: Paraffin-embedded tumour samples of women with hig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vermij, Lisa, Jobsen, Jan J., León-Castillo, Alicia, Brinkhuis, Mariel, Roothaan, Suzan, Powell, Melanie E., de Boer, Stephanie M., Khaw, Pearly, Mileshkin, Linda R., Fyles, Anthony, Leary, Alexandra, Genestie, Catherine, Jürgenliemk-Schulz, Ina M., Crosbie, Emma J., Mackay, Helen J., Nijman, Hans. W., Nout, Remi A., Smit, Vincent T. H. B. M., Creutzberg, Carien L., Horeweg, Nanda, Bosse, Tjalling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050005/ https://www.ncbi.nlm.nih.gov/pubmed/36690721 http://dx.doi.org/10.1038/s41416-023-02141-0

Ejemplares similares

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
por: Vermij, Lisa, et al.
Publicado: (2022)

HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes
por: Vermij, Lisa, et al.
Publicado: (2020)

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer
por: Post, Cathalijne C B, et al.
Publicado: (2021)

Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors
por: Wortman, Bastiaan G., et al.
Publicado: (2019)

QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction
por: Van den Heerik, Anne Sophie V.M., et al.
Publicado: (2023)

Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
por: Horeweg, Nanda, et al.
Publicado: (2022)

Incorporation of molecular characteristics into endometrial cancer management
por: Vermij, Lisa, et al.
Publicado: (2019)

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
por: León-Castillo, Alicia, et al.
Publicado: (2020)

Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
por: van den Heerik, Anne Sophie V M, et al.
Publicado: (2021)

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer
por: Horeweg, Nanda, et al.
Publicado: (2023)

Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
por: Church, David N., et al.
Publicado: (2014)

Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
por: Jamieson, Amy, et al.
Publicado: (2023)

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
por: Eggink, Florine A., et al.
Publicado: (2016)

The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends
por: Creutzberg, Carien L., et al.
Publicado: (2011)

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up
por: Colombo, Nicoletta, et al.
Publicado: (2016)

Performance of a HER2 testing algorithm specific for p53‐abnormal endometrial cancer
por: Vermij, Lisa, et al.
Publicado: (2021)

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
por: Blinman, Prunella, et al.
Publicado: (2016)

Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer
por: van Esterik, Manouk, et al.
Publicado: (2017)

Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer
por: Stelloo, Ellen, et al.
Publicado: (2016)

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
por: de Boer, Stephanie M, et al.
Publicado: (2018)

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
por: de Boer, Stephanie M, et al.
Publicado: (2019)

The evolving role of morphology in endometrial cancer diagnostics: From histopathology and molecular testing towards integrative data analysis by deep learning
por: Fremond, Sarah, et al.
Publicado: (2022)

Ultrasound guided conformal brachytherapy of cervix cancer: survival, patterns of failure, and late complications
por: Narayan, Kailash, et al.
Publicado: (2014)

We should not settle for low-level evidence but should always use the best available evidence
por: Narayan, Kailash, et al.
Publicado: (2014)

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
por: Wortman, B. G., et al.
Publicado: (2018)

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies
por: Kitson, Sarah, et al.
Publicado: (2017)

Timing of radiotherapy in breast-conserving therapy: a large prospective cohort study of node-negative breast cancer patients without adjuvant systemic therapy
por: Jobsen, J J, et al.
Publicado: (2013)

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters
por: Versluis, M A, et al.
Publicado: (2015)

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
por: de Boer, S M, et al.
Publicado: (2018)

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
por: van den Heerik, Anne Sophie V M, et al.
Publicado: (2020)

Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer
por: Peters, Elke E M, et al.
Publicado: (2019)

ENhAncing Lifestyle Behaviors in EndometriaL CancEr (ENABLE): A Pilot Randomized Controlled Trial
por: Edbrooke, Lara, et al.
Publicado: (2022)

Oestrogens and oestrogen receptors in prostate cancer
por: Kowalska, Karolina, et al.
Publicado: (2016)

Of Oestrogens and Sperm: A Review of the Roles of Oestrogens and Oestrogen Receptors in Male Reproduction
por: Dostalova, Pavla, et al.
Publicado: (2017)

The oestrogen paradox: an hypothesis
por: Santen, Richard J
Publicado: (2007)

Adjuvant Systemic Therapy after Chemoradiation and Brachytherapy for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis
por: Horeweg, Nanda, et al.
Publicado: (2021)

Plasma oestrogens and oestrogen receptors in breast cancer patients.
por: Mason, R. C., et al.
Publicado: (1985)

The New Œstrogens
por: Dodds, E. C.
Publicado: (1941)

Cancer of the corpus uteri: 2021 update
por: Koskas, Martin, et al.
Publicado: (2021)

Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation.
por: Pink, J. J., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_n3v79n14p9du5n2012gff02l16